Wegovy Results Timeline, Month by Month and Dose by Dose

On the Wegovy results timeline, the dose climbs for 16 weeks in 4-week steps before reaching 2.4 mg in week 17 (label, section 2.2). By week 20, STEP 4 participants who reached 2.4 mg and stayed in the trial had lost an observed average of 10.6% (trial); STEP 1 averaged 14.9% at week 68 against 2.4% on placebo (label, Table 8). From a 220 lb start, 14.9% is 32.8 lb, or 14.9 kg from 100 kg.

Key facts

• Wegovy reaches 2.4 mg in week 17; adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss can step up to 7.2 mg from week 21 at the earliest (label, section 2.2).
• STEP 4 recorded 10.6% weight loss by week 20 among the 803 participants who reached 2.4 mg and were randomized (STEP 4 trial).
• STEP 1 averaged 14.9% loss versus 2.4% on placebo at week 68, with 83.5% assigned to 2.4 mg losing at least 5% (label, Table 8).
• At week 72, average loss was 18.8% on 7.2 mg versus 15.5% on 2.4 mg in the label’s analysis of STEP UP.
• The daily 25 mg pill averaged 13.6% weight loss versus 2.4% on placebo at week 64 in the label’s analysis.
• With type 2 diabetes, 2.4 mg averaged 9.6% loss versus 3.4% on placebo at week 68 in the label’s analysis.

What does the Wegovy results timeline look like by month?

Wegovy results by month follow a dose ladder, with maintenance starting in week 17 rather than month 6 (US prescribing information, section 2.2).

For the injection steps, a month here means a 4-week block on the label’s schedule; week 68 is about 16 months and week 72 about 17.

The rows combine results from separate trials, so they do not follow one group through every stage (label, sections 2.2 and 14.2, STEP 4).

The pill has its own daily ladder and reached 13.6% at week 64, 29.9 lb from 220 lb or 13.6 kg from 100 kg (label analysis).

What Wegovy results can you expect in the first month?

Wegovy starts at 0.25 mg for weeks 1 to 4, the lowest step of the ladder (prescribing information, section 2.2). The label prints no first-month mean to use as a target.

Stomach side effects were reported most often during this climb (label, section 6.1). After 2 or more consecutive missed injections, the label requires restarting escalation at a lower dose to reduce gastrointestinal reactions (section 2.4).

US labeling allows 1.7 mg or the recommended 2.4 mg as adult maintenance doses (section 2.2). The UK schedule gives 2.4 mg maintenance, with a possible increase to 7.2 mg for patients with obesity (UK SmPC, section 4.2).

If hunger changes before your weight does, check when appetite suppression starts for the separate appetite timeline.

When do you start to see Wegovy results?

By week 20, STEP 4 participants who reached 2.4 mg had lost an observed average of 10.6%, or 23.3 lb from a 220 lb start and 10.6 kg from 100 kg (trial).

The run-in included 16 weeks of escalation followed by 4 weeks at maintenance, so most of that time was spent on step-up doses (STEP 4 methods).

Of 902 people who entered the run-in, 803 reached randomization and 99 stopped beforehand, so the observed average excludes those who stopped (label, Study 5).

The standard schedule reaches 2.4 mg after 16 weeks, about 3.7 calendar months, rather than month 6 (label, section 2.2). Dose weeks follow the label’s count, while results retain each trial’s assessment week. STEP papers count from week 0, so they describe reaching 2.4 mg at week 16 (STEP methods).

How much weight can you lose on Wegovy in 3 to 6 months?

The confirmed Wegovy checkpoint is week 20, about 4.6 months, with 10.6% observed loss among STEP 4 participants who reached 2.4 mg and were randomized (STEP 4). For that selected group, that is 23.3 lb from a 220 lb start and 10.6 kg from a 100 kg start.

At week 12, the scheduled dose is still 1 mg; at the end of the fourth 4-week block, it is 1.7 mg (label schedule). At 6 months, approximately 26 weeks, the standard schedule includes only about 10 weeks on 2.4 mg on the dose ladder.

For adults treated under NICE TA875 within a specialist weight management service, NICE says: "Consider stopping semaglutide if less than 5% of the initial weight has been lost after 6 months of treatment" (NICE TA875, recommendation 1.2).

What Wegovy results come at a year and beyond?

Wegovy averaged 14.9% loss at week 68 on 2.4 mg, versus 2.4% on placebo, in the label’s analysis of STEP 1. Week 68 is about 16 months, so this is beyond a year rather than an exact annual result.

That is 32.8 lb from a 220 lb start, or 14.9 kg from 100 kg; placebo’s 2.4% is 5.3 lb or 2.4 kg.

The label’s Table 8 reports the share of participants assigned to each treatment who reached these thresholds.

People who stayed on 2.4 mg after week 20 had lost 17.4% in total by week 68 under the treatment-policy analysis, or 38.3 lb from a 220 lb start and 17.4 kg from 100 kg (STEP 4). After switching to placebo, weight rose by 6.9% from week 20 to week 68, measured from week 20 weight (STEP 4).

If your own loss has slowed, see what to check at a plateau.

What results does Wegovy 7.2 mg give?

In STEP UP, adults with obesity and without type 2 diabetes averaged 18.8% weight loss at week 72 on 7.2 mg, versus 15.5% on 2.4 mg and 3.9% on placebo (label, Table 12, all randomized). This compares the doses within the same trial.

The label’s 18.8% is total change from starting weight across the whole trial, climb included: 41.4 lb from a 220 lb start or 18.8 kg from 100 kg, against 34.1 lb or 15.5 kg on 2.4 mg. The gap over 2.4 mg was 3.3 percentage points (Table 12).

Adults follow the Wegovy dose ladder and 7.2 mg through 2.4 mg, then may increase after at least 4 tolerated weeks when additional loss is clinically indicated (label). That makes week 21 the earliest start.

The trials escalated treatment over 20 weeks, followed by 52 weeks of maintenance (label, Studies 8 and 9). In the label’s analysis, 45.5% assigned to 7.2 mg lost at least 20%, compared with 32.3% assigned to 2.4 mg (Table 12).

The label counts everyone randomized and fills missing weights using people in the same group who stopped treatment but were still weighed, called retrieved drop-outs multiple imputation, or RD-MI (Table 12). The STEP UP paper reports 18.7% on 7.2 mg and 15.6% on 2.4 mg under its treatment-policy estimand (publication). The label’s 18.8% and the paper’s 18.7% describe the same 7.2 mg arm, 0.1 point apart (label analysis, paper analysis).

US labeling names the higher-dose pen Wegovy HD (dosage forms). The MHRA approved 7.2 mg on 6 January 2026 for adults with obesity only, initially given as 3 injections of 2.4 mg (MHRA announcement). It approved a single-dose 7.2 mg pen on 14 April 2026 (MHRA pen announcement).

What is the Wegovy pill results timeline?

The US label’s pill schedule steps up every 30 days and reaches 25 mg daily on day 91 (label, section 2.3). Average loss was 13.6% at week 64 in the label’s all-randomized analysis of OASIS 4 (Table 11).

The label’s tablet schedule separates the starting doses from maintenance.

In OASIS 4, escalation lasted 12 weeks, followed by 52 weeks of maintenance (label, Study 7).

Against 2.4% on placebo, the pill’s 13.6% is 29.9 lb from a 220 lb start, or 13.6 kg from 100 kg (Table 11).

At that endpoint, 76.3% assigned to the pill lost at least 5%, compared with 31.3% assigned to placebo (Table 11). At least 15% loss was reached by 47% assigned to the pill (Table 11).

For administration instructions and the pill-versus-injection detail, use how to take the Wegovy pill.

How do your own Wegovy results compare with the trials?

Compare your Wegovy record at the same treatment week and dose, because the label’s schedule places starting and maintenance treatment in different periods.

At week 12, the scheduled dose is 1 mg (label schedule). STEP 4’s observed 10.6% at week 20 came from people who reached 2.4 mg on schedule (STEP 4). If a step was delayed, compare against the week you reached each dose instead. At week 68, the STEP 1 label benchmark is 14.9% on 2.4 mg (Table 8).

Check diabetes status too. STEP 1 enrolled adults without diabetes and included lifestyle intervention in both groups (STEP 1 paper). The separate type 2 diabetes trial averaged 9.6% loss on 2.4 mg at week 68 (label, Table 8).

Your weight trend can be viewed alongside dose changes in Pensday. Its free weight report colors your weight line by dose, so weeks on 0.25 mg sit apart from weeks on 2.4 mg. The shots log keeps the date of each step, and dose reminders and a next-shot countdown keep the schedule in view.

Use the GLP‑1 weight loss calculator for a personal 12-month projection; its fitted curve is a model, separate from the trial results here.

To compare spending alongside weight change, use the cost per pound calculator with your own costs and results.